CLDN1 and prostate cancer: Alterations in key AJ and TJ components such as α-catenin, E-cadherin, β-catenin and Claudin 1 have been hailed as potential biomarkers for prostate cancer progression [18], [22], [23], [24] but the majority of research has been carried out on individual molecules.